首页 > 最新文献

Cancer Control最新文献

英文 中文
The Role of m6A-Mediated DNA Damage Repair in Tumor Development and Chemoradiotherapy Resistance m6A 介导的 DNA 损伤修复在肿瘤发生和化疗抗药性中的作用
IF 2.6 4区 医学 Q3 ONCOLOGY Pub Date : 2024-04-25 DOI: 10.1177/10732748241247170
Li Qu, Si jian Liu, Ling Zhang, Jia Feng Liu, Ying Jie Zhou, Peng Hui Zeng, Qian Cheng Jing, Wen Jun Yin
Among the post-transcriptional modifications, m6A RNA methylation has gained significant research interest due to its critical role in regulating transcriptional expression. This modification affects RNA metabolism in several ways, including processing, nuclear export, translation, and decay, making it one of the most abundant transcriptional modifications and a crucial regulator of gene expression. The dysregulation of m6A RNA methylation-related proteins in many tumors has been shown to lead to the upregulation of oncoprotein expression, tumor initiation, proliferation, cancer cell progression, and metastasis.Although the impact of m6A RNA methylation on cancer cell growth and proliferation has been extensively studied, its role in DNA repair processes, which are crucial to the pathogenesis of various diseases, including cancer, remains unclear. However, recent studies have shown accumulating evidence that m6A RNA methylation significantly affects DNA repair processes and may play a role in cancer drug resistance. Therefore, a comprehensive literature review is necessary to explore the potential biological role of m6A-modified DNA repair processes in human cancer and cancer drug resistance.In conclusion, m6A RNA methylation is a crucial regulator of gene expression and a potential player in cancer development and drug resistance. Its dysregulation in many tumors leads to the upregulation of oncoprotein expression and tumor progression. Furthermore, the impact of m6A RNA methylation on DNA repair processes, although unclear, may play a crucial role in cancer drug resistance. Therefore, further studies are warranted to better understand the potential biological role of m6A-modified DNA repair processes in human cancer and cancer drug resistance.
在转录后修饰中,m6A RNA 甲基化因其在调控转录表达中的关键作用而备受研究关注。这种修饰以多种方式影响 RNA 代谢,包括加工、核输出、翻译和衰变,使其成为最丰富的转录修饰之一,也是基因表达的关键调节因子。虽然 m6A RNA 甲基化对癌细胞生长和增殖的影响已被广泛研究,但它在 DNA 修复过程中的作用仍不清楚,而 DNA 修复过程对包括癌症在内的各种疾病的发病机制至关重要。然而,最近的研究显示,越来越多的证据表明,m6A RNA 甲基化会显著影响 DNA 修复过程,并可能在癌症耐药性中发挥作用。总之,m6A RNA 甲基化是基因表达的关键调节因子,也是癌症发展和耐药性的潜在参与者。它在许多肿瘤中的失调会导致肿瘤蛋白表达的上调和肿瘤的进展。此外,m6A RNA 甲基化对 DNA 修复过程的影响虽然尚不清楚,但可能在癌症耐药性中发挥关键作用。因此,有必要开展进一步研究,以更好地了解 m6A 修饰的 DNA 修复过程在人类癌症和癌症耐药性中的潜在生物学作用。
{"title":"The Role of m6A-Mediated DNA Damage Repair in Tumor Development and Chemoradiotherapy Resistance","authors":"Li Qu, Si jian Liu, Ling Zhang, Jia Feng Liu, Ying Jie Zhou, Peng Hui Zeng, Qian Cheng Jing, Wen Jun Yin","doi":"10.1177/10732748241247170","DOIUrl":"https://doi.org/10.1177/10732748241247170","url":null,"abstract":"Among the post-transcriptional modifications, m6A RNA methylation has gained significant research interest due to its critical role in regulating transcriptional expression. This modification affects RNA metabolism in several ways, including processing, nuclear export, translation, and decay, making it one of the most abundant transcriptional modifications and a crucial regulator of gene expression. The dysregulation of m6A RNA methylation-related proteins in many tumors has been shown to lead to the upregulation of oncoprotein expression, tumor initiation, proliferation, cancer cell progression, and metastasis.Although the impact of m6A RNA methylation on cancer cell growth and proliferation has been extensively studied, its role in DNA repair processes, which are crucial to the pathogenesis of various diseases, including cancer, remains unclear. However, recent studies have shown accumulating evidence that m6A RNA methylation significantly affects DNA repair processes and may play a role in cancer drug resistance. Therefore, a comprehensive literature review is necessary to explore the potential biological role of m6A-modified DNA repair processes in human cancer and cancer drug resistance.In conclusion, m6A RNA methylation is a crucial regulator of gene expression and a potential player in cancer development and drug resistance. Its dysregulation in many tumors leads to the upregulation of oncoprotein expression and tumor progression. Furthermore, the impact of m6A RNA methylation on DNA repair processes, although unclear, may play a crucial role in cancer drug resistance. Therefore, further studies are warranted to better understand the potential biological role of m6A-modified DNA repair processes in human cancer and cancer drug resistance.","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"44 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140802271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigating Disparities in Hypopharyngeal/Laryngeal Cancer Survival in Florida With Geospatial Mapping Analysis 利用地理空间制图分析调查佛罗里达州下咽/喉癌存活率的差异
IF 2.6 4区 医学 Q3 ONCOLOGY Pub Date : 2024-04-16 DOI: 10.1177/10732748241246958
Uche C. Ezeh, Abdurrahman Al-Awady, Isabella Buitron, Ming Lee, Garrett Forman, Sophia Peifer, Alana Deo, Larissa Sweeny, Donald Weed, Erin K. Kobetz, Isildinha M Reis, Elizabeth Franzmann
ObjectiveIdentify predictors of overall survival (OS) after hypopharyngeal/laryngeal cancer in Florida.Material and MethodsWe conducted a retrospective cohort study using data from the Florida Cancer Data System (FCDS) on patients diagnosed with hypopharyngeal or laryngeal cancer from 2010-2017. Primary outcome was OS. Hazard ratios (HRs) were estimated from univariable and multivariable Cox regression models for OS. Data was analyzed from November 1, 2022, to June 30, 2023.ResultsWe analyzed 6771 patients, who were primarily male (81.2%), White non-Hispanic (WNH) (78.2%), publicly insured (70.1%), married (51.8%), and residents of urban counties (73.6%). Black patients were more likely to be younger at diagnosis (38.9%), single (43.4%), to have distant SEER stage disease (25.6%). Median OS were lowest among patients who were uninsured (34 months), with hypopharyngeal site disease (18 months), and a smoking history (current: 34 months, former: 46 months, no smoking: 63 months). Multivariable Cox regression analysis showed worse OS for single/unmarried vs married (HR 1.47 [95%CI: 1.36-1.59], P < .001), history of tobacco use (current: HR 1.62 [95%CI: 1.440-1.817], P < .001; former smokers: (HR 1.28 [95%CI: 1.139-1.437], P < .001) vs no history). Improved OS was observed among White Hispanics (WH) vs WNH (HR .73 [95%CI: .655-.817], P < .001) and women vs men (HR .88 [95%CI: .807-.954], P = .002). Geographical mapping showed that mortality rates were highest in census tracts with low income and education.ConclusionOur findings suggest that sociodemographic and clinical factors impact OS from hypopharyngeal/laryngeal cancer in Florida and vary geographically within the state. These results will help guide future public health interventions.
目的确定佛罗里达州下咽癌/喉癌术后总生存期(OS)的预测因素。材料与方法我们利用佛罗里达癌症数据系统(FCDS)中的数据,对2010-2017年期间诊断为下咽癌或喉癌的患者进行了一项回顾性队列研究。主要结果为OS。通过单变量和多变量考克斯回归模型估算出OS的危险比(HRs)。数据分析时间为 2022 年 11 月 1 日至 2023 年 6 月 30 日。结果我们分析了 6771 名患者,他们主要为男性(81.2%)、非西班牙裔白人(WNH)(78.2%)、公共保险(70.1%)、已婚(51.8%)和城市县居民(73.6%)。黑人患者在确诊时更年轻(38.9%)、单身(43.4%)、患有远期 SEER 分期疾病(25.6%)。无保险(34个月)、患有下咽部位疾病(18个月)和有吸烟史(目前:34个月;以前:46个月;不吸烟:63个月)的患者的中位生存期最低。多变量 Cox 回归分析显示,单身/未婚 vs 已婚(HR 1.47 [95%CI:1.36-1.59],P < .001)、有吸烟史(目前:HR 1.62 [95%CI:1.440-1.817],P < .001;曾经吸烟者:(HR 1.28 [95%CI:1.139-1.437],P < .001) vs 无吸烟史)的患者的 OS 较差。在西班牙裔白人(WH)与西班牙裔黑人(HR:.73 [95%CI:.655-.817],P < .001)和女性与男性(HR:.88 [95%CI:.807-.954],P = .002)之间观察到OS有所改善。我们的研究结果表明,佛罗里达州的社会人口和临床因素对下咽癌/喉癌的死亡率有影响,并且在该州内存在地域差异。这些结果将有助于指导未来的公共卫生干预措施。
{"title":"Investigating Disparities in Hypopharyngeal/Laryngeal Cancer Survival in Florida With Geospatial Mapping Analysis","authors":"Uche C. Ezeh, Abdurrahman Al-Awady, Isabella Buitron, Ming Lee, Garrett Forman, Sophia Peifer, Alana Deo, Larissa Sweeny, Donald Weed, Erin K. Kobetz, Isildinha M Reis, Elizabeth Franzmann","doi":"10.1177/10732748241246958","DOIUrl":"https://doi.org/10.1177/10732748241246958","url":null,"abstract":"ObjectiveIdentify predictors of overall survival (OS) after hypopharyngeal/laryngeal cancer in Florida.Material and MethodsWe conducted a retrospective cohort study using data from the Florida Cancer Data System (FCDS) on patients diagnosed with hypopharyngeal or laryngeal cancer from 2010-2017. Primary outcome was OS. Hazard ratios (HRs) were estimated from univariable and multivariable Cox regression models for OS. Data was analyzed from November 1, 2022, to June 30, 2023.ResultsWe analyzed 6771 patients, who were primarily male (81.2%), White non-Hispanic (WNH) (78.2%), publicly insured (70.1%), married (51.8%), and residents of urban counties (73.6%). Black patients were more likely to be younger at diagnosis (38.9%), single (43.4%), to have distant SEER stage disease (25.6%). Median OS were lowest among patients who were uninsured (34 months), with hypopharyngeal site disease (18 months), and a smoking history (current: 34 months, former: 46 months, no smoking: 63 months). Multivariable Cox regression analysis showed worse OS for single/unmarried vs married (HR 1.47 [95%CI: 1.36-1.59], P &lt; .001), history of tobacco use (current: HR 1.62 [95%CI: 1.440-1.817], P &lt; .001; former smokers: (HR 1.28 [95%CI: 1.139-1.437], P &lt; .001) vs no history). Improved OS was observed among White Hispanics (WH) vs WNH (HR .73 [95%CI: .655-.817], P &lt; .001) and women vs men (HR .88 [95%CI: .807-.954], P = .002). Geographical mapping showed that mortality rates were highest in census tracts with low income and education.ConclusionOur findings suggest that sociodemographic and clinical factors impact OS from hypopharyngeal/laryngeal cancer in Florida and vary geographically within the state. These results will help guide future public health interventions.","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"4 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140591050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Association of Oncology Provider Density With Black-White Disparities in Cancer Mortality in US Counties 美国各县肿瘤科医生密度与癌症死亡率黑白差异的关系
IF 2.6 4区 医学 Q3 ONCOLOGY Pub Date : 2024-04-12 DOI: 10.1177/10732748241244929
Yuehan Zhang, Kathryn M. Leifheit, Kimberley T. Lee, Roland J. Thorpe, Darrell J. Gaskin, Lorraine T. Dean
BackgroundBlack-White racial disparities in cancer mortality are well-documented in the US. Given the estimated shortage of oncologists over the next decade, understanding how access to oncology care might influence cancer disparities is of considerable importance. We aim to examine the association between oncology provider density in a county and Black-White cancer mortality disparities.MethodsAn ecological study of 1048 US counties was performed. Oncology provider density was estimated using the 2013 National Plan and Provider Enumeration System data. Black:White cancer mortality ratio was calculated using 2014-2018 age-standardized cancer mortality rates from State Cancer Profiles. Linear regression with covariate adjustment was constructed to assess the association of provider density with (1) Black:White cancer mortality ratio, and (2) cancer mortality rates overall, and separately among Black and White persons.ResultsThe mean Black:White cancer mortality ratio was 1.12, indicating that cancer mortality rate among Black persons was on average 12% higher than that among White persons. Oncology provider density was significantly associated with greater cancer mortality disparities: every 5 additional oncology providers per 100 000 in a county was associated with a .02 increase in the Black:White cancer mortality ratio (95% CI: .007 to .03); however, the unexpected finding may be explained by further analysis showing that the relationship between oncology provider density and cancer mortality was different by race group. Every 5 additional oncologists per 100 000 was associated with a 1.6 decrease per 100 000 in cancer mortality rates among White persons (95% CI: −3.0 to −.2), whereas oncology provider density was not associated with cancer mortality among Black persons.ConclusionGreater oncology provider density was associated with significantly lower cancer mortality among White persons, but not among Black persons. Higher oncology provider density alone may not resolve cancer mortality disparities, thus attention to ensuring equitable care is critical.
背景在美国,黑人和白人在癌症死亡率方面的种族差异是有据可查的。据估计,未来十年内肿瘤学家将出现短缺,因此了解肿瘤治疗的获取途径如何影响癌症的差异具有相当重要的意义。我们旨在研究一个县的肿瘤医疗机构密度与黑人-白人癌症死亡率差异之间的关系。我们使用 2013 年国家计划和提供者查点系统数据估算了肿瘤科提供者的密度。黑人与白人的癌症死亡率比值是根据各州癌症概况中 2014-2018 年年龄标准化癌症死亡率计算得出的。构建了带有协变量调整的线性回归,以评估提供者密度与(1)黑人:白人癌症死亡率比率,以及(2)总体癌症死亡率和黑人与白人癌症死亡率的关联。肿瘤科医生的密度与癌症死亡率的差异明显相关:每 10 万人中每增加 5 名肿瘤科医生,黑人与白人的癌症死亡率比值就会增加 0.02(95% CI:0.007 至 0.03);然而,进一步的分析表明,肿瘤科医生的密度与癌症死亡率之间的关系因种族群体而异,这或许可以解释这一意外发现。每 10 万人中增加 5 名肿瘤学家,白人的癌症死亡率就会下降 1.6(95% CI:-3.0 至 -.2),而肿瘤医生密度与黑人的癌症死亡率无关。仅靠提高肿瘤治疗提供者的密度可能无法解决癌症死亡率差异问题,因此关注确保公平治疗至关重要。
{"title":"The Association of Oncology Provider Density With Black-White Disparities in Cancer Mortality in US Counties","authors":"Yuehan Zhang, Kathryn M. Leifheit, Kimberley T. Lee, Roland J. Thorpe, Darrell J. Gaskin, Lorraine T. Dean","doi":"10.1177/10732748241244929","DOIUrl":"https://doi.org/10.1177/10732748241244929","url":null,"abstract":"BackgroundBlack-White racial disparities in cancer mortality are well-documented in the US. Given the estimated shortage of oncologists over the next decade, understanding how access to oncology care might influence cancer disparities is of considerable importance. We aim to examine the association between oncology provider density in a county and Black-White cancer mortality disparities.MethodsAn ecological study of 1048 US counties was performed. Oncology provider density was estimated using the 2013 National Plan and Provider Enumeration System data. Black:White cancer mortality ratio was calculated using 2014-2018 age-standardized cancer mortality rates from State Cancer Profiles. Linear regression with covariate adjustment was constructed to assess the association of provider density with (1) Black:White cancer mortality ratio, and (2) cancer mortality rates overall, and separately among Black and White persons.ResultsThe mean Black:White cancer mortality ratio was 1.12, indicating that cancer mortality rate among Black persons was on average 12% higher than that among White persons. Oncology provider density was significantly associated with greater cancer mortality disparities: every 5 additional oncology providers per 100 000 in a county was associated with a .02 increase in the Black:White cancer mortality ratio (95% CI: .007 to .03); however, the unexpected finding may be explained by further analysis showing that the relationship between oncology provider density and cancer mortality was different by race group. Every 5 additional oncologists per 100 000 was associated with a 1.6 decrease per 100 000 in cancer mortality rates among White persons (95% CI: −3.0 to −.2), whereas oncology provider density was not associated with cancer mortality among Black persons.ConclusionGreater oncology provider density was associated with significantly lower cancer mortality among White persons, but not among Black persons. Higher oncology provider density alone may not resolve cancer mortality disparities, thus attention to ensuring equitable care is critical.","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"54 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140591052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Troponin Elevation in Patients Undergoing Percutaneous Hepatic Perfusion for Metastatic Uveal Melanoma 接受经皮肝灌注治疗转移性葡萄膜黑色素瘤患者的肌钙蛋白升高
IF 2.6 4区 医学 Q3 ONCOLOGY Pub Date : 2024-04-12 DOI: 10.1177/10732748241246898
Sanjay Chandrasekhar, Matthew Perez, Zurain Niaz, Jahanzaib Ekram, Neelam Lal, Sarah Koly, Biwei Cao, Jonathan S. Zager, Mohammed Alomar
BackgroundPercutaneous Hepatic Perfusion (PHP) is a liver directed regional therapy recently FDA approved for metastatic uveal melanoma to the liver involving percutaneous isolation of liver, saturation of the entire liver with high-dose chemotherapy and filtration extracorporeally though in line filters and veno-venous bypass. The procedure is associated with hemodynamic shifts requiring hemodynamic support and blood product resuscitation due to coagulopathy.ObjectiveTo assess the cardiac safety and subsequent clinically significant sequalae of this therapy.MethodsConsecutive PHP procedures done at our center between 2010-2022 were assessed retrospectively. Cardiac risk factors, post procedural cardiac enzymes, electrocardiograms, and transthoracic echocardiograms along with 90-day cardiac outcomes were reviewed. All data were reviewed by cardio-oncologists at our institution.ResultsOf 37 patients reviewed, mean age was 63 years and 57% were women. 132 procedures were performed with an average of 3.57 procedures per patient. 68.6% of patients had elevated troponin during at least 1 procedure. No patients were found to have acute coronary syndrome, heart failure, unstable arrhythmias, or cardiac death. No patients had notable echocardiographic changes. 10.8% of patients with positive troponin had asymptomatic transient electrocardiographic changes not meeting criteria for myocardial infarction. One patient had non-sustained ventricular tachycardiac intra-operatively which did not recur subsequently. Three patients died from non-cardiac causes within 90-days. There was no oncology treatment interruption, even in those with troponin elevation. In multivariable analysis, a history of hyperlipidemia was a predictor of postoperative troponin elevation. ( P = .042).ConclusionPercutaneous Hepatic Perfusion is safe and associated with a transient, asymptomatic troponin elevation peri-operatively without major adverse cardiac events at 90 days. The observed troponin elevation is likely secondary to coronary demand-supply mismatch related to procedural hemodynamic shifts, hypotension, and anemia.
背景经皮肝脏灌注(PHP)是一种肝脏定向区域疗法,最近美国食品及药物管理局批准用于治疗肝脏转移性葡萄膜黑色素瘤,包括经皮分离肝脏、用高剂量化疗使整个肝脏饱和、通过管路过滤器和静脉-静脉旁路进行体外过滤。方法回顾性评估本中心在 2010-2022 年间完成的连续 PHP 手术。对心脏风险因素、术后心肌酶、心电图和经胸超声心动图以及 90 天的心脏结果进行了回顾性分析。所有数据均由本院的心外科肿瘤专家审核。共进行了 132 次手术,平均每位患者 3.57 次。68.6%的患者在至少一次手术中肌钙蛋白升高。没有发现患者患有急性冠状动脉综合征、心力衰竭、不稳定心律失常或心源性死亡。没有患者出现明显的超声心动图变化。10.8%肌钙蛋白呈阳性的患者出现无症状的一过性心电图改变,但未达到心肌梗死的标准。一名患者术中出现非持续性室性心动过速,但随后没有复发。三名患者在 90 天内死于非心脏原因。即使是肌钙蛋白升高的患者也没有中断肿瘤治疗。在多变量分析中,高脂血症史是术后肌钙蛋白升高的一个预测因素。(结论经皮肝灌注术是安全的,围手术期会出现一过性、无症状的肌钙蛋白升高,90 天后不会出现重大心脏不良事件。观察到的肌钙蛋白升高可能是继发于冠状动脉供需不匹配,与手术过程中的血流动力学转变、低血压和贫血有关。
{"title":"Troponin Elevation in Patients Undergoing Percutaneous Hepatic Perfusion for Metastatic Uveal Melanoma","authors":"Sanjay Chandrasekhar, Matthew Perez, Zurain Niaz, Jahanzaib Ekram, Neelam Lal, Sarah Koly, Biwei Cao, Jonathan S. Zager, Mohammed Alomar","doi":"10.1177/10732748241246898","DOIUrl":"https://doi.org/10.1177/10732748241246898","url":null,"abstract":"BackgroundPercutaneous Hepatic Perfusion (PHP) is a liver directed regional therapy recently FDA approved for metastatic uveal melanoma to the liver involving percutaneous isolation of liver, saturation of the entire liver with high-dose chemotherapy and filtration extracorporeally though in line filters and veno-venous bypass. The procedure is associated with hemodynamic shifts requiring hemodynamic support and blood product resuscitation due to coagulopathy.ObjectiveTo assess the cardiac safety and subsequent clinically significant sequalae of this therapy.MethodsConsecutive PHP procedures done at our center between 2010-2022 were assessed retrospectively. Cardiac risk factors, post procedural cardiac enzymes, electrocardiograms, and transthoracic echocardiograms along with 90-day cardiac outcomes were reviewed. All data were reviewed by cardio-oncologists at our institution.ResultsOf 37 patients reviewed, mean age was 63 years and 57% were women. 132 procedures were performed with an average of 3.57 procedures per patient. 68.6% of patients had elevated troponin during at least 1 procedure. No patients were found to have acute coronary syndrome, heart failure, unstable arrhythmias, or cardiac death. No patients had notable echocardiographic changes. 10.8% of patients with positive troponin had asymptomatic transient electrocardiographic changes not meeting criteria for myocardial infarction. One patient had non-sustained ventricular tachycardiac intra-operatively which did not recur subsequently. Three patients died from non-cardiac causes within 90-days. There was no oncology treatment interruption, even in those with troponin elevation. In multivariable analysis, a history of hyperlipidemia was a predictor of postoperative troponin elevation. ( P = .042).ConclusionPercutaneous Hepatic Perfusion is safe and associated with a transient, asymptomatic troponin elevation peri-operatively without major adverse cardiac events at 90 days. The observed troponin elevation is likely secondary to coronary demand-supply mismatch related to procedural hemodynamic shifts, hypotension, and anemia.","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"51 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140591466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Systematic Review of Treatment-Related Adverse Events for Combination Therapy of Multiple Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor 多种酪氨酸激酶抑制剂和免疫检查点抑制剂联合疗法治疗相关不良事件的系统性综述
IF 2.6 4区 医学 Q3 ONCOLOGY Pub Date : 2024-04-06 DOI: 10.1177/10732748241244586
Takashi Sawada, Mamoru Narukawa
BackgroundCombination therapy with multiple tyrosine kinase inhibitors (multi-TKIs) and immune checkpoint inhibitors (ICIs) has been increasingly tested in clinical studies. This study aimed to investigate the effect of the addition of ICI to multi-TKIs on the profile of treatment-related adverse events.MethodsAn electronic database search was performed using PubMed and Web of Science to identify published clinical studies on multi-TKI monotherapy and multi-TKI plus ICI combination therapy from July 20, 2005 to July 1, 2023. The incidence rate of common adverse events caused by multi-TKI monotherapy and multi-TKI plus ICI combination therapy was obtained and compared from the viewpoints of (1) relative risk for the combination therapy vs sunitinib, (2) adverse event incidence rate by clinical trial, and (3) pooled incidence rate. The quality of the evidence was assessed with the Cochrane risk of bias tool. Meta-analysis used random effects models.ResultsThis systematic review identified 83 clinical studies involving 7951 patients. The combination therapy of multi-TKI and ICI was associated with an increased risk of diarrhea (relative risk [RR]: 1.24, 95% confidence interval [CI]: 1.15-1.33, P < .001), hypothyroidism (RR: 1.44, 95% CI: 1.11-1.87, P = .0064) and rash (RR: 1.71, 95% CI: 1.18-2.47, P = .0045) compared with multi-TKI monotherapy. The addition of ICI was suggested to decrease the risk of adverse events related to performance status.ConclusionOur study identified an increased risk of treatment-related adverse events associated with multi-TKI plus ICI combination therapy. This would help optimize the management of toxicities caused by multi-TKI plus ICI combination therapy.
背景多种酪氨酸激酶抑制剂(multi-TKIs)与免疫检查点抑制剂(ICIs)的联合疗法已越来越多地在临床研究中得到验证。方法利用PubMed和Web of Science进行电子数据库检索,找出2005年7月20日至2023年7月1日期间发表的关于多酪氨酸激酶抑制剂单药治疗和多酪氨酸激酶抑制剂加ICI联合治疗的临床研究。从以下角度比较了多TKI单药治疗和多TKI加ICI联合治疗引起的常见不良事件的发生率:(1)联合治疗与舒尼替尼的相对风险;(2)各临床试验的不良事件发生率;(3)汇总发生率。证据质量采用 Cochrane 偏倚风险工具进行评估。荟萃分析采用随机效应模型。结果本系统综述确定了83项临床研究,涉及7951名患者。多种 TKI 和 ICI 的联合治疗与腹泻风险增加有关(相对风险 [RR]: 1.24,95% 置信区间):1.24,95% 置信区间 [CI]:001)、甲状腺功能减退(RR:1.44,95% 置信区间:1.11-1.87,P = .0064)和皮疹(RR:1.71,95% 置信区间:1.18-2.47,P = .0045)。结论我们的研究发现,多TKI加ICI联合疗法会增加治疗相关不良事件的风险。这将有助于优化多TKI加ICI联合疗法引起的毒性反应的管理。
{"title":"A Systematic Review of Treatment-Related Adverse Events for Combination Therapy of Multiple Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor","authors":"Takashi Sawada, Mamoru Narukawa","doi":"10.1177/10732748241244586","DOIUrl":"https://doi.org/10.1177/10732748241244586","url":null,"abstract":"BackgroundCombination therapy with multiple tyrosine kinase inhibitors (multi-TKIs) and immune checkpoint inhibitors (ICIs) has been increasingly tested in clinical studies. This study aimed to investigate the effect of the addition of ICI to multi-TKIs on the profile of treatment-related adverse events.MethodsAn electronic database search was performed using PubMed and Web of Science to identify published clinical studies on multi-TKI monotherapy and multi-TKI plus ICI combination therapy from July 20, 2005 to July 1, 2023. The incidence rate of common adverse events caused by multi-TKI monotherapy and multi-TKI plus ICI combination therapy was obtained and compared from the viewpoints of (1) relative risk for the combination therapy vs sunitinib, (2) adverse event incidence rate by clinical trial, and (3) pooled incidence rate. The quality of the evidence was assessed with the Cochrane risk of bias tool. Meta-analysis used random effects models.ResultsThis systematic review identified 83 clinical studies involving 7951 patients. The combination therapy of multi-TKI and ICI was associated with an increased risk of diarrhea (relative risk [RR]: 1.24, 95% confidence interval [CI]: 1.15-1.33, P &lt; .001), hypothyroidism (RR: 1.44, 95% CI: 1.11-1.87, P = .0064) and rash (RR: 1.71, 95% CI: 1.18-2.47, P = .0045) compared with multi-TKI monotherapy. The addition of ICI was suggested to decrease the risk of adverse events related to performance status.ConclusionOur study identified an increased risk of treatment-related adverse events associated with multi-TKI plus ICI combination therapy. This would help optimize the management of toxicities caused by multi-TKI plus ICI combination therapy.","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"37 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140590931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter to the Editor: Cross-Sectional Study for Investigation of the Association Between Modifiable Risk Factors and Gastrointestinal Cancers at a Tertiary Hospital in Ghana. 致编辑的信:加纳一家三级医院为调查可改变的风险因素与胃肠道癌症之间的关系而开展的横断面研究。
IF 2.6 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 DOI: 10.1177/10732748241233957
Akash Kumar, Javeria Mansoor, Hassaan Sadiq
{"title":"Letter to the Editor: Cross-Sectional Study for Investigation of the Association Between Modifiable Risk Factors and Gastrointestinal Cancers at a Tertiary Hospital in Ghana.","authors":"Akash Kumar, Javeria Mansoor, Hassaan Sadiq","doi":"10.1177/10732748241233957","DOIUrl":"10.1177/10732748241233957","url":null,"abstract":"","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"31 ","pages":"10732748241233957"},"PeriodicalIF":2.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874145/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139747657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radar-Guided Localization and Resection for Metastatic Nodal and Soft Tissue Melanoma: A Single-Institution Retrospective Study. 针对转移性结节和软组织黑色素瘤的雷达引导定位和切除术:一项单机构回顾性研究。
IF 2.6 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 DOI: 10.1177/10732748241237907
Kate E Beekman, Danielle K DePalo, Lily M Parker, Kelly M Elleson, John E Mullinax, Amod A Sarnaik, Vernon K Sondak, Jonathan S Zager

Background: Radar-guided localization (RGL) offers a wire-free, nonradioactive surgical guidance method consisting of a small percutaneously-placed radar reflector and handheld probe. This study investigates the feasibility, timing, and outcomes of RGL for melanoma metastasectomy.

Methods: We retrospectively identified patients at our cancer center who underwent RGL resection of metastatic melanoma between December 2020-June 2023. Data pertaining to patients' melanoma history, management, reflector placement and retrieval, and follow-up was extracted from patient charts and analyzed using descriptive statistics.

Results: Twenty-three RGL cases were performed in patients with stage III-IV locoregional or oligometastatic disease, 10 of whom had reflectors placed prior to neoadjuvant therapy. Procedures included soft tissue nodule removals (8), index lymph node removals (13), and therapeutic lymph node dissections (2). Reflectors were located and retrieved intraoperatively in 96% of cases from a range of 2 to 282 days after placement; the last reflector was not able to be located during surgery via probe or intraoperative ultrasound. One retrieved reflector had migrated from the index lesion, thus overall success rate of reflector and associated index lesion removal was 21 of 23 (91%). All RGL-localized and retrieved index lesions that contained viable tumor (10) had microscopically negative margins. There were no complications attributable to reflector insertion and no unexpected complications of RGL surgery.

Conclusion: In our practice, RGL is a safe and effective surgical localization method for soft tissue and nodal melanoma metastases. The inert nature of the reflector enables implantation prior to neoadjuvant therapy with utility in index lymph node removal.

背景:雷达引导定位(RGL)是一种无导线、非放射性的手术引导方法,由一个经皮放置的小型雷达反射器和手持探头组成。本研究调查了 RGL 用于黑色素瘤转移切除术的可行性、时机和结果:我们回顾性地确定了本癌症中心在 2020 年 12 月至 2023 年 6 月期间接受 RGL 转移性黑色素瘤切除术的患者。我们从患者病历中提取了与患者黑色素瘤病史、处理、反射器放置和取回以及随访相关的数据,并使用描述性统计进行了分析:23例RGL病例均为III-IV期局部或少转移性疾病患者,其中10例在新辅助治疗前放置了反射器。手术包括软组织结节切除术(8 例)、指数淋巴结切除术(13 例)和治疗性淋巴结清扫术(2 例)。在96%的病例中,反射器在放置后2到282天内都能在手术中找到并取回;最后一个反射器在手术中无法通过探针或术中超声找到。有一个取回的反射器是从索引病变中移出的,因此反射器和相关索引病变移除的总成功率为 23 例中的 21 例(91%)。所有RGL定位和取回的索引病灶中都有存活的肿瘤(10个),显微镜下边缘均为阴性。RGL手术未出现可归因于反射器插入的并发症,也未出现意外并发症:在我们的临床实践中,RGL 是一种安全有效的手术定位方法,适用于软组织和结节性黑色素瘤转移。反射器的惰性使其可以在新辅助治疗前植入,并可用于索引淋巴结切除。
{"title":"Radar-Guided Localization and Resection for Metastatic Nodal and Soft Tissue Melanoma: A Single-Institution Retrospective Study.","authors":"Kate E Beekman, Danielle K DePalo, Lily M Parker, Kelly M Elleson, John E Mullinax, Amod A Sarnaik, Vernon K Sondak, Jonathan S Zager","doi":"10.1177/10732748241237907","DOIUrl":"10.1177/10732748241237907","url":null,"abstract":"<p><strong>Background: </strong>Radar-guided localization (RGL) offers a wire-free, nonradioactive surgical guidance method consisting of a small percutaneously-placed radar reflector and handheld probe. This study investigates the feasibility, timing, and outcomes of RGL for melanoma metastasectomy.</p><p><strong>Methods: </strong>We retrospectively identified patients at our cancer center who underwent RGL resection of metastatic melanoma between December 2020-June 2023. Data pertaining to patients' melanoma history, management, reflector placement and retrieval, and follow-up was extracted from patient charts and analyzed using descriptive statistics.</p><p><strong>Results: </strong>Twenty-three RGL cases were performed in patients with stage III-IV locoregional or oligometastatic disease, 10 of whom had reflectors placed prior to neoadjuvant therapy. Procedures included soft tissue nodule removals (8), index lymph node removals (13), and therapeutic lymph node dissections (2). Reflectors were located and retrieved intraoperatively in 96% of cases from a range of 2 to 282 days after placement; the last reflector was not able to be located during surgery via probe or intraoperative ultrasound. One retrieved reflector had migrated from the index lesion, thus overall success rate of reflector <i>and</i> associated index lesion removal was 21 of 23 (91%). All RGL-localized and retrieved index lesions that contained viable tumor (10) had microscopically negative margins. There were no complications attributable to reflector insertion and no unexpected complications of RGL surgery.</p><p><strong>Conclusion: </strong>In our practice, RGL is a safe and effective surgical localization method for soft tissue and nodal melanoma metastases. The inert nature of the reflector enables implantation prior to neoadjuvant therapy with utility in index lymph node removal.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"31 ","pages":"10732748241237907"},"PeriodicalIF":2.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10908225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140013475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Isolated Limb Infusion as First, Second, or Third or Later-Line Therapy for Metastatic In-Transit Melanoma. 将孤立肢体输注作为转移性过境黑色素瘤的一线、二线、三线或后线疗法。
IF 2.5 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 DOI: 10.1177/10732748241297326
Aleena Boby, Michelle M Dugan, Helana Ghali, Shaliz Aflatooni, Danielle K DePalo, Wenyi Fan, Jonathan S Zager

Background: Ten percent of patients with melanoma develop in-transit metastases (ITM). Isolated limb infusion (ILI) is a well-established therapy for unresectable ITM on the extremities, but the ideal sequencing/line of therapy of ILI has not been defined. This study evaluates ILI as first-line, second-line, or third or later-line therapy.

Methods: A retrospective review included all patients with unresectable ITM who underwent ILI from 2006-2023.

Results: A total of 130 patients were identified, 61% female, median age of 71 (31-89) years. Median follow-up was 37.5 months. ILI was first-line therapy in 80% (n = 104), second-line in 15% (n = 19), and third or later-line in 5.4% (n = 7). Overall response rate (ORR) and complete response (CR) rates for ILI as any line of therapy were 74% and 41%, respectively. ORR for ILI as first, second, or third or later-line therapy were 78%, 63%, and 57%, respectively. CR rates for ILI as first, second, or third or later-line therapy were 42%, 37%, and 43%, respectively. There were no significant differences in ORR, progression-free survival (PFS), overall survival, or disease-free survival between therapy lines. Median PFS for ILI as first, second, or third or later-line therapy were 6.9, 5.4, and 18 months, respectively.

Conclusion: Patients responded well to ILI, whether or not they received previous therapies for unresectable ITM. First-line ILI appears to have a better ORR than later lines of ILI. Although sample size limited statistical significance, there was a 21% improvement in ORR when ILI was used as first-line vs third-line therapy, which is clinically meaningful. ILI is effective for unresectable melanoma ITM and can be used as salvage therapy.

背景:10%的黑色素瘤患者会出现转移灶(ITM)。孤立肢体输注(ILI)是治疗四肢不可切除 ITM 的一种行之有效的疗法,但 ILI 理想的治疗顺序/治疗线尚未确定。本研究对ILI作为一线、二线、三线或更后一线疗法进行了评估:一项回顾性研究纳入了2006-2023年间所有接受ILI治疗的不可切除ITM患者:结果:共发现130例患者,61%为女性,中位年龄为71(31-89)岁。中位随访时间为 37.5 个月。80%的患者(104人)接受了ILI一线治疗,15%的患者(19人)接受了二线治疗,5.4%的患者(7人)接受了三线或三线以上治疗。ILI作为任何一线疗法的总体应答率(ORR)和完全应答率(CR)分别为74%和41%。ILI作为一线、二线、三线或三线以上疗法的ORR分别为78%、63%和57%。ILI作为一线、二线、三线或后一线疗法的CR率分别为42%、37%和43%。不同治疗方案的ORR、无进展生存期(PFS)、总生存期或无病生存期无明显差异。ILI作为一线、二线、三线或三线以上疗法的中位PFS分别为6.9个月、5.4个月和18个月:患者对ILI反应良好,无论他们之前是否接受过不可切除ITM的治疗。一线ILI的ORR似乎优于后几线ILI。虽然样本量限制了统计学意义,但ILI作为一线疗法与三线疗法相比,ORR提高了21%,这在临床上是有意义的。ILI对不可切除的黑色素瘤ITM有效,可作为挽救疗法。
{"title":"Isolated Limb Infusion as First, Second, or Third or Later-Line Therapy for Metastatic In-Transit Melanoma.","authors":"Aleena Boby, Michelle M Dugan, Helana Ghali, Shaliz Aflatooni, Danielle K DePalo, Wenyi Fan, Jonathan S Zager","doi":"10.1177/10732748241297326","DOIUrl":"10.1177/10732748241297326","url":null,"abstract":"<p><strong>Background: </strong>Ten percent of patients with melanoma develop in-transit metastases (ITM). Isolated limb infusion (ILI) is a well-established therapy for unresectable ITM on the extremities, but the ideal sequencing/line of therapy of ILI has not been defined. This study evaluates ILI as first-line, second-line, or third or later-line therapy.</p><p><strong>Methods: </strong>A retrospective review included all patients with unresectable ITM who underwent ILI from 2006-2023.</p><p><strong>Results: </strong>A total of 130 patients were identified, 61% female, median age of 71 (31-89) years. Median follow-up was 37.5 months. ILI was first-line therapy in 80% (n = 104), second-line in 15% (n = 19), and third or later-line in 5.4% (n = 7). Overall response rate (ORR) and complete response (CR) rates for ILI as any line of therapy were 74% and 41%, respectively. ORR for ILI as first, second, or third or later-line therapy were 78%, 63%, and 57%, respectively. CR rates for ILI as first, second, or third or later-line therapy were 42%, 37%, and 43%, respectively. There were no significant differences in ORR, progression-free survival (PFS), overall survival, or disease-free survival between therapy lines. Median PFS for ILI as first, second, or third or later-line therapy were 6.9, 5.4, and 18 months, respectively.</p><p><strong>Conclusion: </strong>Patients responded well to ILI, whether or not they received previous therapies for unresectable ITM. First-line ILI appears to have a better ORR than later lines of ILI. Although sample size limited statistical significance, there was a 21% improvement in ORR when ILI was used as first-line vs third-line therapy, which is clinically meaningful. ILI is effective for unresectable melanoma ITM and can be used as salvage therapy.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"31 ","pages":"10732748241297326"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11539175/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142584836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient-Perceived Benefits and Limitations of Standard of Care Remote Symptom Monitoring During Cancer Treatment. 患者对癌症治疗期间标准护理远程症状监测的益处和局限性的看法。
IF 2.5 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 DOI: 10.1177/10732748241297368
Catherine S Smith, Nicole L Henderson, Emma K Hendrix, Tanvi Padalkar, Chao-Hui Sylvia Huang, D'Ambra N Dent, Stacey A Ingram, Chelsea McGowan, J Nicholas Odom, Tara Kaufmann, Bryan Weiner, Doris Howell, Angela M Stover, Ethan Basch, Jennifer Young Pierce, Gabrielle B Rocque

Introduction: Remote symptom monitoring (RSM) allows patients to electronically self-report symptoms to their healthcare team for individual management. Clinical trials have demonstrated overarching benefits; however, little is known regarding patient-perceived benefits and limitations of RSM programs used during patient care.

Methods: This prospective qualitative study from December 2021 to May 2023 included patients with cancer participating in standard-of-care RSM at the University of Alabama at Birmingham (UAB) in Birmingham, AL, and the Univeristy of South Alabama (USA) Health Mitchell Cancer Institute (MCI) in Mobile, AL. Semi-structured interviews focused on patient experiences with and perceptions surrounding RSM participation. Interviews occurred over the phone, via digital videoconference, or in person, at the convenience of the patient. Grounded theory was used to conduct content coding and identify recurring themes and exemplary quotes using NVivo.

Results: Forty patients (20 UAB, 20 MCI) were interviewed. Participants were predominately female (87.5%), aged 41-65 (50%), and married (57.5%). Data is consistent with local demographics, comprising mainly White (72.5%) and 27.5% Black individuals. Three main themes emerged regarding perceived benefits of RSM: (1) Facilitation of Proactive Management, identifying the patient's needs and intervening earlier to alleviate symptom burden; (2) Promotion of Symptom Self-Management, providing patients autonomy in their cancer care; and (3) Improvement in Patient-Healthcare Provider Relationships, fostering genuine connections based on healthcare team's responses. However, participants also noted Perceived Limitations of RSM; particularly when support of symptom management was unnecessary, ineffective, or felt impersonal.

Conclusion: This study focused on patient experiences when utilizing a RSM program while undergoing treatment for cancer and found benefits to its implementation that extended beyond symptom management. At the same time, patients noted drawbacks experienced during RSM, which can help with future tailoring of RSM programs. Patient perceptions should be regularly assessed and highlighted for successful and sustained implementation.

简介远程症状监测(RSM)允许患者以电子方式向医疗团队自我报告症状,以便进行个性化管理。临床试验已经证明了其总体益处;然而,对于患者在护理过程中使用的 RSM 程序的患者感知益处和局限性却知之甚少:这项前瞻性定性研究于 2021 年 12 月至 2023 年 5 月进行,研究对象包括在阿拉巴马州伯明翰的阿拉巴马大学伯明翰分校(UAB)和阿拉巴马州莫比尔的南阿拉巴马大学(USA)健康米切尔癌症研究所(MCI)参加标准护理 RSM 的癌症患者。半结构式访谈的重点是患者参与 RSM 的经历和看法。访谈在患者方便的情况下通过电话、数字视频会议或当面进行。采用基础理论进行内容编码,并使用 NVivo 确定重复出现的主题和典范引文:共采访了 40 名患者(20 名 UAB,20 名 MCI)。参与者主要为女性(87.5%)、41-65 岁(50%)和已婚(57.5%)。数据与当地人口构成一致,主要为白人(72.5%)和黑人(27.5%)。关于 RSM 的感知益处,出现了三大主题:(1)促进主动管理,识别患者需求并尽早干预以减轻症状负担;(2)促进症状自我管理,为患者提供癌症护理自主权;以及(3)改善患者与医疗保健提供者的关系,根据医疗保健团队的反应促进真正的联系。然而,参与者也指出了 RSM 的局限性,尤其是当症状管理支持不必要、无效或感觉不人性化时:本研究关注患者在接受癌症治疗时使用 RSM 计划的体验,发现实施该计划的益处超出了症状管理的范围。同时,患者也指出了在 RSM 过程中遇到的弊端,这些弊端有助于今后定制 RSM 计划。应定期评估并强调患者的看法,以便成功持续地实施该计划。
{"title":"Patient-Perceived Benefits and Limitations of Standard of Care Remote Symptom Monitoring During Cancer Treatment.","authors":"Catherine S Smith, Nicole L Henderson, Emma K Hendrix, Tanvi Padalkar, Chao-Hui Sylvia Huang, D'Ambra N Dent, Stacey A Ingram, Chelsea McGowan, J Nicholas Odom, Tara Kaufmann, Bryan Weiner, Doris Howell, Angela M Stover, Ethan Basch, Jennifer Young Pierce, Gabrielle B Rocque","doi":"10.1177/10732748241297368","DOIUrl":"10.1177/10732748241297368","url":null,"abstract":"<p><strong>Introduction: </strong>Remote symptom monitoring (RSM) allows patients to electronically self-report symptoms to their healthcare team for individual management. Clinical trials have demonstrated overarching benefits; however, little is known regarding patient-perceived benefits and limitations of RSM programs used during patient care.</p><p><strong>Methods: </strong>This prospective qualitative study from December 2021 to May 2023 included patients with cancer participating in standard-of-care RSM at the University of Alabama at Birmingham (UAB) in Birmingham, AL, and the Univeristy of South Alabama (USA) Health Mitchell Cancer Institute (MCI) in Mobile, AL. Semi-structured interviews focused on patient experiences with and perceptions surrounding RSM participation. Interviews occurred over the phone, via digital videoconference, or in person, at the convenience of the patient. Grounded theory was used to conduct content coding and identify recurring themes and exemplary quotes using NVivo.</p><p><strong>Results: </strong>Forty patients (20 UAB, 20 MCI) were interviewed. Participants were predominately female (87.5%), aged 41-65 (50%), and married (57.5%). Data is consistent with local demographics, comprising mainly White (72.5%) and 27.5% Black individuals. Three main themes emerged regarding perceived benefits of RSM: (1) <i>Facilitation of Proactive</i> <i>Management</i>, identifying the patient's needs and intervening earlier to alleviate symptom burden; (2) <i>Promotion of Symptom Self-Management</i>, providing patients autonomy in their cancer care; and (3) <i>Improvement in Patient-Healthcare Provider Relationships</i>, fostering genuine connections based on healthcare team's responses. However, participants also noted <i>Perceived Limitations of RSM</i>; particularly when support of symptom management was unnecessary, ineffective, or felt impersonal.</p><p><strong>Conclusion: </strong>This study focused on patient experiences when utilizing a RSM program while undergoing treatment for cancer and found benefits to its implementation that extended beyond symptom management. At the same time, patients noted drawbacks experienced during RSM, which can help with future tailoring of RSM programs. Patient perceptions should be regularly assessed and highlighted for successful and sustained implementation.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"31 ","pages":"10732748241297368"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11569491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142640021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
"They Need to Feel Non-Judgmental": Results of Participatory Photovoice Research to Inform Lung Cancer Screening Imagery. "他们需要感觉不被评判":肺癌筛查图像的参与式摄影选择研究成果。
IF 2.5 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 DOI: 10.1177/10732748241292567
Erin A Hirsch, Kaitlyn Hoover, Jamie L Studts

Introduction: Effective communication and messaging strategies are crucial to raise awareness and support participants' efforts to adhere to lung cancer screening (LCS) guidelines. Health messages that incorporate images are processed more efficiently, and given the stigma surrounding lung cancer and cigarette smoking, emphasis must be placed on selecting imagery that is engaging to LCS-eligible individuals. This exploratory study aimed to identify person-centered themes surrounding LCS imagery.

Materials and methods: This qualitative study leveraged a modified photovoice approach and interviews to define descriptive themes about LCS imagery. Study participants eligible for annual LCS who had a CT scan within 12 months were asked to select three images and participate in a semi-structured interview about photo selection, likes, and dislikes. Participants were also asked their opinions about images from current LCS communications featuring matches, smoke, and cigarettes. Data were analyzed using an inductive thematic approach.

Results: Data saturation was reached after thirteen individuals completed the photovoice activity; each participant selected three pictures resulting in a total of 39 images representing LCS. Over half (54%) of images selected contained lungs and only 4 (10%) contained smoking-related elements. Five main themes emerged: 1) images should focus on good news and early detection; 2) people should be relatable; 3) pictures with lungs can dually support lung health or invoke fear; 4) opportunity for education or awareness; and 5) should not be judgmental and induce stigma.

Conclusions: These findings suggest that LCS imagery should not contain negative or stigmatizing elements but instead be relatable and educational. This information can inform communication and messaging interventions and strategies for future LCS participation, awareness, and educational research.

导言:有效的沟通和信息传递策略对于提高人们对肺癌筛查(LCS)指南的认识和支持参与者遵守指南至关重要。考虑到围绕肺癌和吸烟的污名化问题,必须强调选择对符合 LCS 资格的人有吸引力的图像。这项探索性研究旨在确定围绕LCS图像的以人为本的主题:这项定性研究采用改良的摄影选言法和访谈来确定有关 LCS 图像的描述性主题。符合年度 LCS 条件并在 12 个月内进行过 CT 扫描的研究参与者被要求选择三张图片,并参加关于照片选择、喜欢和不喜欢的半结构化访谈。参与者还被问及他们对当前 LCS 传播中以火柴、烟雾和香烟为主题的图片的看法。我们采用归纳式主题方法对数据进行了分析:在 13 位参与者完成摄影选择活动后,数据达到饱和;每位参与者选择了三张图片,结果共有 39 张图片代表了文康宣传品。超过一半(54%)被选图片包含肺,只有 4 张(10%)包含与吸烟有关的元素。出现了五大主题:1)图片应侧重于好消息和早期发现;2)人物应具有亲和力;3)带有肺的图片既可以支持肺部健康,也可以引起恐惧;4)教育或提高认识的机会;5)不应带有评判性和诱发耻辱感:这些研究结果表明,LCS 图像不应包含负面或污名化的元素,而应具有亲和力和教育意义。这些信息可以为未来的 LCS 参与、认识和教育研究提供沟通和信息干预及策略方面的信息。
{"title":"\"They Need to Feel Non-Judgmental\": Results of Participatory Photovoice Research to Inform Lung Cancer Screening Imagery.","authors":"Erin A Hirsch, Kaitlyn Hoover, Jamie L Studts","doi":"10.1177/10732748241292567","DOIUrl":"https://doi.org/10.1177/10732748241292567","url":null,"abstract":"<p><strong>Introduction: </strong>Effective communication and messaging strategies are crucial to raise awareness and support participants' efforts to adhere to lung cancer screening (LCS) guidelines. Health messages that incorporate images are processed more efficiently, and given the stigma surrounding lung cancer and cigarette smoking, emphasis must be placed on selecting imagery that is engaging to LCS-eligible individuals. This exploratory study aimed to identify person-centered themes surrounding LCS imagery.</p><p><strong>Materials and methods: </strong>This qualitative study leveraged a modified photovoice approach and interviews to define descriptive themes about LCS imagery. Study participants eligible for annual LCS who had a CT scan within 12 months were asked to select three images and participate in a semi-structured interview about photo selection, likes, and dislikes. Participants were also asked their opinions about images from current LCS communications featuring matches, smoke, and cigarettes. Data were analyzed using an inductive thematic approach.</p><p><strong>Results: </strong>Data saturation was reached after thirteen individuals completed the photovoice activity; each participant selected three pictures resulting in a total of 39 images representing LCS. Over half (54%) of images selected contained lungs and only 4 (10%) contained smoking-related elements. Five main themes emerged: 1) images should focus on good news and early detection; 2) people should be relatable; 3) pictures with lungs can dually support lung health or invoke fear; 4) opportunity for education or awareness; and 5) should not be judgmental and induce stigma.</p><p><strong>Conclusions: </strong>These findings suggest that LCS imagery should not contain negative or stigmatizing elements but instead be relatable and educational. This information can inform communication and messaging interventions and strategies for future LCS participation, awareness, and educational research.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"31 ","pages":"10732748241292567"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11483848/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142478642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer Control
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1